BioLife Solutions
Bothell
WA
United States
93 articles about BioLife Solutions
-
BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences
3/4/2024
BioLife Solutions, Inc. today announced that Roderick de Greef , Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.
-
BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results
2/29/2024
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company") today announced financial results for the fourth quarter and year ended December 31, 2023, and introduces 2024 revenue guidance.
-
BioLife Solutions Reports Third Quarter 2023 Financial Results
11/9/2023
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company") today announced financial results for the third quarter and nine months of 2023.
-
BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023
11/2/2023
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter financial results will be released after market close on Thursday, November 9, 2023.
-
BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023
10/19/2023
BioLife Solutions, Inc. announced Roderick de Greef has been appointed as Chairman of the Board of Directors and Chief Executive Officer replacing Michael Rice who is retiring after a seventeen year tenure, effective immediately.
-
BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023
7/27/2023
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter financial results will be released after market close on Tuesday, August 8, 2023.
-
BioLife Solutions Reports First Quarter 2023 Financial Results
5/10/2023
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31, 2023.
-
BioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023
5/2/2023
BioLife Solutions, Inc., a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies and broader biopharma markets, announced the Company's first quarter financial results will be released after market close on Wednesday, May 10, 2023.
-
BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results
3/16/2023
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company") today announced financial results for the fourth quarter and year ended December 31, 2022.
-
BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023
3/9/2023
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2022 financial results will be released after market close on Thursday, March 16, 2023.
-
BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences
1/17/2023
BioLife Solutions, Inc. announced the dates of its 2023 analyst day and upcoming investor conferences where management will be presenting and meeting with current and prospective investors.
-
BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance
1/9/2023
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company") today announced 2022 fourth quarter and full year preliminary unaudited revenue and introduced 2023 revenue guidance.
-
BioLife Solutions Expands Intellectual Property Estate
11/21/2022
BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy and the broader biopharma markets, provided an update on the expansion of its intellectual property estate.
-
BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report
11/17/2022
BioLife Solutions, Inc. today announced that it has been selected for inclusion in the BioSpace Best Places to Work in Biopharma 2023 Report.
-
CEOs at Sana Biotechnology and BioLife Solutions explain how being based in the BioForest region helped them be voted one of BioSpace's best places to work in 2023.
-
BioLife Solutions Reports Third Quarter 2022 Financial Results
11/9/2022
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three and nine months ended September 30, 2022.
-
BioLife Solutions Announces COO to Retire and Join Board of Directors
10/3/2022
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy ("CGT") and broader biopharma markets, today announced changes to its Board of Directors and executive management team, all to be effective as of January 3, 2023.
-
BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors
8/25/2022
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company") today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six.
-
BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance
8/9/2022
BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies and the broader biopharma markets, announced financial results for the three and six months ended June 30, 2022.
-
BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022
5/3/2022
BioLife Solutions, Inc. announced the Company's first quarter 2022 financial results will be released after market close on Monday, May 9th.